Drugs /

nexi-001

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of allogeneic CD8+ T cells targeting multiple undisclosed leukemia-associated antigens, with potential immunomodulating and antineoplastic activities. Following peripheral blood mononuclear cell (PBMC) collection from the original stem cell donor and ex vivo priming and expansion, the allogeneic CD8+ leukemia-associated antigens specific T cells NEXI-001 are re-introduced into the leukemia patient, where they target and kill tumor cells expressing these leukemia-associated antigens.

Clinical Trials

View Clinical Trials for nexi-001

Nexi-001 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating nexi-001, 1 is phase 1/phase 2 (1 open).

HLA-A*02:01 Positive is the most frequent biomarker inclusion criterion for nexi-001 clinical trials.

Acute myeloid leukemia and myelodysplastic syndromes are the most common diseases being investigated in nexi-001 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Nexi-001
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating nexi-001 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
nexi001, nexi 001, allogeneic cd8+ leukemia-associated antigens specific t cells nexi-001, nexi-001 t cells
Drug Target(s) [2]:
CCNA1, PRAME, WT1
NCIT ID [1]:
C170887

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.